Key result
Finerenone demonstrates robust cardiovascular and kidney protection in diabetic kidney disease.
Why the study?
Despite improvements from traditional RAAS inhibitors and SGLT2 inhibitors in diabetic kidney disease, residual risks remain unaddressed.
Does finerenone improve kidney and cardiovascular outcomes in patients with diabetic kidney disease?
Does finerenone improve kidney and cardiovascular outcomes in patients with diabetic kidney disease?
Finerenone represents a breakthrough therapy for diabetic kidney disease, offering significant nephro- and cardio-protective benefits and potential synergy with SGLT2 inhibitors.
May support finerenone in diabetic kidney disease; leaves open practice change without RCTs.
BACKGROUND: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease worldwide. The management of DKD relies on controlling glycemia and blood pressure levels, as well as reducing proteinuria. While the traditional renin-angiotensin-aldosterone system inhibitors (RAASi) and the recently approved type 2 Na+/glucose co-transporter inhibitors (SGLT2i) have significantly improved patient outcomes, residual risks remain unaddressed. SUMMARY: This review explores (1) the mechanisms of action of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (ns-MRA), (2) the evidence of finerenone-induced kidney protection in clinical trials, and (3) the comparative advantages over conventional MRAs. The potential synergy between finerenone and SGLT2i is also addressed, alongside research perspectives and practical considerations for implementation in clinical practice. KEY MESSAGES: Finerenone has emerged as a breakthrough therapy in the management of DKD, demonstrating robust nephro- and cardio-protective effects.
No takes yet. Share an insight, caveat, or question.
Huart et al. (2025) conducted a review in Diabetic kidney disease (DKD). Finerenone vs. Conventional MRAs was evaluated. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, demonstrates robust nephro- and cardio-protective effects in the management of diabetic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: